Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/IIa Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of EVM14 as Monotherapy and in Combination With Pembrolizumab in Patients With Selected Solid Tumors

NCT07095868 is registered in ClinicalTrials.gov with Everest Medicines (Beijing) Co., Ltd. as lead sponsor.

NCT NCT07095868
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07095868 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/IIa Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of EVM14 as Monotherapy and in Combination With Pembrolizumab in Patients With Selected Solid Tumors
Lead sponsor
Everest Medicines (Beijing) Co., Ltd.
Phase
Phase 1/2
Overall status
Recruiting
Start date
November 17, 2025
Completion date
November 30, 2031
Enrollment
94 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

selected types of solid tumor